Free Trial
ASX:MSB

Mesoblast (MSB) Stock Price, News & Analysis

Mesoblast logo

About Mesoblast Stock (ASX:MSB)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
10.19 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
2.58%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Receive MSB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

MSB Stock News Headlines

Mesoblast Finally Gets Its Approval In GVHD: Where Now?
This is the worst sign for the U.S. stock market in 50 years
The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"
3 ASX 300 shares smashing new highs while the market dives
See More Headlines

MSB Stock Analysis - Frequently Asked Questions

Mesoblast Limited (ASX:MSB) released its earnings results on Thursday, February, 21st. The company reported ($0.09) EPS for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mesoblast investors own include Mesoblast (MESO), Fortescue (FMG), MicroStrategy (MSTR), Aus Tin Mining (ANW), OceanaGold (OGC), Piedmont Lithium (PLL) and Alliance Resource Partners (ARLP).

Company Calendar

Last Earnings
2/21/2019
Today
12/22/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Trading
CIK
N/A
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

Net Income
$-87,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.90 million
Book Value
A$0.42 per share

Miscellaneous

Outstanding Shares
1,140,000,000
Free Float
N/A
Optionable
Not Optionable
Beta
2.38
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (ASX:MSB) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners